Semaglutide and Mazindol Both Reduce Weight in East Asian Patients, But Head-to-Head Comparison Not Feasible
A systematic review found that both semaglutide and mazindol significantly reduce body weight in East Asian people with obesity, but differences in study design prevented a direct comparison between the two drugs.
Quick Facts
What This Study Found
Semaglutide (STEP 6) significantly reduced body weight and cardiometabolic risk factors (HbA1c, cholesterol, blood pressure) in Japanese and South Korean patients with obesity. Mazindol also reduced weight and cholesterol in Japan. Direct comparison was not feasible due to study heterogeneity.
Key Numbers
Asians have higher obesity-related comorbidity risk at lower BMI compared to Europeans; the review highlights this disparity in available drug evidence.
How They Did This
Systematic literature review of Embase, MEDLINE, and ICHUSHI databases for RCTs of semaglutide or mazindol in East Asian adults with obesity. Indirect treatment comparison (ITC) feasibility was assessed based on heterogeneity of effect modifiers and study design variations.
Why This Research Matters
East Asians face higher obesity-related health risks at lower BMI levels than Western populations, making effective anti-obesity treatments particularly important in this group. This review establishes the evidence base for the two most relevant medications.
The Bigger Picture
As the obesity epidemic grows in East Asia, there is an urgent need for evidence specific to this population. The paucity of trials — only 2 qualifying studies found — highlights how underrepresented East Asian patients are in anti-obesity medication research.
What This Study Doesn't Tell Us
Only 2 studies met inclusion criteria, severely limiting analysis. Semaglutide and mazindol could not be directly compared. English and Japanese language restriction may have excluded some studies. No data on newer GLP-1 agonists (tirzepatide) in East Asian populations at time of review.
Questions This Raises
- ?Would tirzepatide show even greater weight loss in East Asian patients, and at what BMI thresholds?
- ?Should obesity treatment BMI cutoffs be formally lowered for East Asian populations?
- ?How do the adverse event profiles of semaglutide and mazindol compare specifically in East Asian patients?
Trust & Context
- Key Stat:
- Only 2 trials found Despite growing obesity prevalence in East Asia, only 2 qualifying RCTs of anti-obesity medications exist for this population
- Evidence Grade:
- Moderate evidence — systematic review methodology but limited by only 2 qualifying studies. Indirect treatment comparison was not feasible.
- Study Age:
- Published in 2024, reflecting the current evidence gap for anti-obesity medications in East Asian populations.
- Original Title:
- Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.
- Published In:
- Advances in therapy, 41(9), 3452-3470 (2024)
- Authors:
- Yokote, Koutaro, Ota, Riku, Wada, Shogo, Matsuda, Hiroyuki, Filomeno, Ronald
- Database ID:
- RPEP-09606
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Why do East Asian people need different obesity research?
East Asians typically develop obesity-related health problems like diabetes and heart disease at lower BMI levels than Western populations. This means treatment may need to start at lower BMI thresholds, and drug effectiveness data from Western trials may not fully apply.
Is semaglutide approved for obesity treatment in Japan?
This review examined evidence from the STEP 6 trial in Japanese and South Korean patients, which showed significant weight loss and cardiometabolic improvements. Regulatory approvals vary by country and indication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09606APA
Yokote, Koutaro; Ota, Riku; Wada, Shogo; Matsuda, Hiroyuki; Filomeno, Ronald. (2024). Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.. Advances in therapy, 41(9), 3452-3470. https://doi.org/10.1007/s12325-024-02941-7
MLA
Yokote, Koutaro, et al. "Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.." Advances in therapy, 2024. https://doi.org/10.1007/s12325-024-02941-7
RethinkPeptides
RethinkPeptides Research Database. "Clinical Efficacy and Safety of Anti-Obesity Medications Amo..." RPEP-09606. Retrieved from https://rethinkpeptides.com/research/yokote-2024-clinical-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.